ABT-510

Thrombospondin 1 Mimetic Peptide / Antiangiogenic PeptideRx: ResearchCompound: Investigational

Also known as: ABT-510, thrombospondin mimetic, TSP-1 mimetic peptide

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

ABT-510 is a nonapeptide analogue of the antiangiogenic domain of thrombospondin-1. It was investigated as an antiangiogenic anticancer agent in multiple Phase I and Phase II clinical trials. It demonstrated acceptable tolerability but limited single-agent efficacy in various solid tumors, and clinical development was largely discontinued.

Mechanism of Action

Mimics the antiangiogenic domain of thrombospondin-1 (TSP-1); binds CD36 on endothelial cells, inhibiting VEGF-induced endothelial cell proliferation, migration, and tube formation, thereby suppressing tumor angiogenesis and inducing endothelial cell apoptosis.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Solid tumor treatmentOncologyLow
  • Tumor angiogenesis inhibitionOncology / AntiangiogenicModerate
  • Combination antiangiogenic therapyOncology / CombinationLow

Contraindications

  • Known hypersensitivity to ABT-510 or peptide excipientsAllergyHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

  • HypertensionCardiovascularUncommonHigh blood pressure
  • Injection site reactionsLocalCommon
  • ThrombocytopeniaHematologicUncommonLow platelet count
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
  • FatigueGeneralCommonLow energy or tiredness

Drug Interactions

  • Cytotoxic chemotherapy agentsModerate
  • Anticoagulants / antiplatelet agentsModerate

Population Constraints

  • Severe hepatic or renal impairmentOrgan ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Pregnant or lactating womenReproductiveAbsolute

Regulatory Status

  • European UnionInvestigationalNo EMA approval; investigational use only in clinical trials.
  • United StatesInvestigationalInvestigated under IND by Abbott Laboratories; Phase I/II trials completed; development discontinued without FDA approval.
  • United KingdomInvestigationalNo MHRA approval; clinical trial use only.

Never received regulatory approval in any jurisdiction. Investigated under IND by Abbott Laboratories in Phase I/II oncology trials. Development was discontinued after Phase II results showed limited clinical benefit.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack